London, 30 March 2015 – The Global Melanoma Therapeutics Market is expected to grow at a CAGR of 15.40 percent from 2015-2019, according to a new report from research firm Technavio.
About the Report
The demand for drugs and treatment options for melanoma has increased considerably because of the high prevalence of the disease in populations worldwide. It is the seventh most common type of cancer in the US and Australia.
“Increased exposure to UV rays, ozone layer depletion and genetic mutations are the major causes of melanoma, which is expected to fuel the therapeutics market through the projected period,” says Faisal Ghaus, Vice President of Technavio.
The latest report by Technavio draws attention towards the emergence of combination therapies that are being used more effectively for the treatment of patients with melanoma. During stage IV of the disease, tumor cells spread from their origin to distant sites, which makes single therapy treatment ineffective. Combination therapies help in the complete removal of tumors and the destruction of cancerous cells.
“Medical oncologists in both US and major countries in Europe prefer Yervoy in combination with Zelboraf or Temodar or generic Dacarbazine in the treatment of advanced melanoma,” says Ghaus.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2019
Market Growth Drivers:
- High Prevalence of Melanoma
- For a full detailed list, view our report.
Market Challenges:
- Availability of Alternative Treatments
- For a full detailed list, view our report.
Market Trends:
- Emergence of Combination Therapies
- For a full detailed list, view our report.
Key Vendors:
- Bristol-Myers Squibb Co.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
Other Prominent Vendors:
- AB Science
- Amgen
- Bayer
- Celgene
- Daiichi Sankyo
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
